Contact Us: 1-888-535-3444

(NEW YORK – April 16, 2015) Icahn School of Medicine at Mount Sinai (ISSMM) will be able to further develop new blood treatments for chemotherapy-resistant blood cancer and other genetic blood disorders thanks to an $8.8 million grant from the New York State Stem Cell Science Program (NYSTEM). The grant will advance on-going development of a process to increase the number of stem cells collected in cord blood collections. The funding will also enhance collaborations with biotechnology firms NeoStem, Inc. and AllCells, LLC, leaders in cellular therapy.

Blood stem cell transplantation has proven to be the only potential therapy available for most patients with blood cancers. To obtain blood stem cells for transplant, doctors use cord blood collections which contain only limited numbers of stem cells. Mount Sinai researchers have developed a method to increase the number of collected stem cells 35-fold. The grant will move this research ahead to clinical trials.

Continue reading »


AllCells is committed to providing researchers with products and services in order to advance their scientific experiments, we’d like to draw attention to a recent collaboration with Amgen, the world’s largest biotechnology firm. This collaboration resulted in a successful research project which led to a poster presentation at the Novel Immunotherapeutics Summit in San Diego, CA from January 30-31th, 2014.

Continue reading »


Live Webinar – Isolating Primary Cells 101: Which viability method is best for your research?

Presented by AllCells & Nexcelom Bioscience

What process is used to obtain cells from bone marrow and normal peripheral blood?
What is the best cell counting and viability method for primary cells?

AllCells, your primary cells research partner, and Nexcelom Bioscience, your cell counting experts, have joined together in an exclusive collaboration to host a free webinar to help educate researchers and present data from their own experiences. Join our Laboratory Scientists for this collaboration including a Q&A session following the presentation.


Thursday, 2/13
9:00-9:30AM PST

Presented by:

James Lee, AllCells Laboratory Manager
Leo Chan, Nexcelom Technology R&D Manager

Topics to be covered in the webinar:

  • Background on cell isolation methods from two tissue types: bone marrow, blood
  • Equipment used in the process
  • Most accurate cell count and viability methods for bone marrow, blood, and other primary cell types
  • Introduction of data, case studies
  • Q&A

cell lineage v2012Product copy cellometer

Continue reading »


AllCells will be at the 55th Annual American Society of Hematology meeting in New Orleans Louisiana between December 6th – 11th, 2013. Visit us at booth #3931 to learn about the latest pre-clinical updates in research and how AllCells continually has grown to meet the demands of our customers though diversifying product and service lines.

The American Society of Hematology (ASH) is the world’s largest professional society concerned with the causes and treatments of blood disorders. The mission of the Society is to further the understanding, diagnosis, treatment, and prevention of disorders affecting the blood, bone marrow, and the immunologic, hemostatic and vascular systems, by promoting research, clinical care, education, training, and advocacy in hematology. Join AllCells as well as nearly 300 pharmaceutical companies, medical suppliers, clinical diagnostic and research-based companies, publishers, and nonprofit organizations as an exhibitor at the 2013 ASH Annual Meeting.

AllCells Announces Plans to Relocate and Expand U.S Operations

 News & Events  Comments Off on AllCells Announces Plans to Relocate and Expand U.S Operations
Dec 122012

Company consolidates, expands clinical tissue collection and manufacturing.

EMERYVILLE, CA – December 13, 2012/PRNewswire/ — AllCells LLC, a leading life science industry provider of human hematologic tissue such as bone marrow, Leuko Paks, peripheral blood, healthy & diseased primary cells, and cell-based assay services, today announced plans to relocate its U.S operations to Alameda, California. The relocation will occur towards the end of Q1, 2013.

Continue reading »